JPMorgan analyst Anupam Rama added a “Positive Catalyst Watch” on shares of Ideaya Biosciences (IDYA) into the updates for darovasertib. The firm keeps an Overweight rating on the shares with a $74 price target After hosting a call with management, JPMorgan sees “plenty of value creating events” in the near-term for Ideaya. Darovasertib updates should continue to underscore the drug’s “compelling emerging profile,” the analyst tells investors in a research note. JPMorgan continues to see Ideaya shares as undervalued on darovasertib alone.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences initiated with a Buy at Guggenheim
- Ideaya Biosciences price target raised to $44 from $43 at Mizuho
- IDEAYA Biosciences: Promising Clinical Developments and Strategic Positioning Highlighted by Buy Rating
- Ideaya Biosciences price target raised to $38 from $36 at RBC Capital
- Promising Pipeline and Competitive Edge: IDEAYA Biosciences Receives Buy Rating from Analyst